Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy

[1]  T. Gajewski.  The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. , 2015, Seminars in oncology.

[2]  S. Pignata,et al.  Identification of a distinct population of CD133+CXCR4+ cancer stem cells in ovarian cancer , 2015, Scientific Reports.

[3]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[4]  R. Markwald,et al.  Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer , 2015, Front. Immunol..

[5]  T. Gajewski,et al.  Innate immune recognition of cancer. , 2015, Annual review of immunology.

[6]  T. Gajewski,et al.  The STING pathway and the T cell-inflamed tumor microenvironment. , 2015, Trends in immunology.

[7]  A. Hemminki,et al.  Oncolytic adenovirus and doxorubicin‐based chemotherapy results in synergistic antitumor activity against soft‐tissue sarcoma , 2015, International journal of cancer.

[8]  M. Seshadri,et al.  CXCL12/CXCR4 Blockade by Oncolytic Virotherapy Inhibits Ovarian Cancer Growth by Decreasing Immunosuppression and Targeting Cancer-Initiating Cells , 2014, The Journal of Immunology.

[9]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[10]  C. Breitbach,et al.  Going viral with cancer immunotherapy , 2014, Nature Reviews Cancer.

[11]  A. Dubrovska,et al.  Emerging targets in cancer management: role of the CXCL12/CXCR4 axis , 2013, OncoTargets and therapy.

[12]  G. Mor,et al.  Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment , 2013, Cancer medicine.

[13]  S. Murphy,et al.  Increased Intragenic IGF2 Methylation is Associated with Repression of Insulator Activity and Elevated Expression in Serous Ovarian Carcinoma , 2013, Front. Oncol..

[14]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[15]  M. Seshadri,et al.  Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases , 2013, Proceedings of the National Academy of Sciences.

[16]  S. Pignata,et al.  Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer , 2013, Journal of drug delivery.

[17]  J. Melchjorsen,et al.  Learning from the Messengers: Innate Sensing of Viruses and Cytokine Regulation of Immunity—Clues for Treatments and Vaccines , 2013, Viruses.

[18]  C. Korch,et al.  DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. , 2012, Gynecologic oncology.

[19]  A. Szalay,et al.  Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells , 2012, Journal of Translational Medicine.

[20]  G. Coukos,et al.  Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. , 2012, Gynecologic oncology.

[21]  R. K. Pandey,et al.  Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice , 2011, British Journal of Cancer.

[22]  S. Gibson,et al.  RNA species generated in vaccinia virus infected cells activate cell type-specific MDA5 or RIG-I dependent interferon gene transcription and PKR dependent apoptosis. , 2011, Virology.

[23]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[24]  R. Jain,et al.  CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies? , 2011, Clinical Cancer Research.

[25]  A. Bowie,et al.  IFI16 is an innate immune sensor for intracellular DNA , 2010, Nature Immunology.

[26]  Li Yang,et al.  TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. , 2010, Trends in immunology.

[27]  H. Rokita,et al.  Targeting a Mimotope Vaccine to Activating Fcγ Receptors Empowers Dendritic Cells to Prime Specific CD8+ T Cell Responses in Tumor-Bearing Mice1 , 2009, The Journal of Immunology.

[28]  Massimo Cristofanilli,et al.  A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. , 2009, The Journal of surgical research.

[29]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[30]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[31]  L. P. de Sousa,et al.  Activation of the PI3K/Akt Pathway Early during Vaccinia and Cowpox Virus Infections Is Required for both Host Survival and Viral Replication , 2009, Journal of Virology.

[32]  R. Chen,et al.  Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance , 2009, Cell cycle.

[33]  D. Wong,et al.  Translating an Antagonist of Chemokine Receptor CXCR4: From Bench to Bedside , 2008, Clinical Cancer Research.

[34]  R. Schreiber,et al.  Immune‐mediated dormancy: an equilibrium with cancer , 2008, Journal of leukocyte biology.

[35]  D. Sze,et al.  Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. , 2008, The Lancet. Oncology.

[36]  Curt Balch,et al.  Identification and characterization of ovarian cancer-initiating cells from primary human tumors. , 2008, Cancer research.

[37]  P. van Endert,et al.  Ecto‐calreticulin in immunogenic chemotherapy , 2007, Immunological reviews.

[38]  H. Hirte,et al.  405 POSTER Final results of a Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers , 2007 .

[39]  L. Zitvogel,et al.  Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis , 2007, Cell Death and Differentiation.

[40]  K. Odunsi,et al.  Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[41]  D. Simeone,et al.  Cancer stem cells: a new paradigm for understanding tumor progression and therapeutic resistance. , 2007, Surgery.

[42]  A. A. Andrade,et al.  Differential role played by the MEK/ERK/EGR-1 pathway in orthopoxviruses vaccinia and cowpox biology. , 2006, The Biochemical journal.

[43]  P. Drew,et al.  The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays , 2006, Molecular Cancer Therapeutics.

[44]  Matthew L. Anderson,et al.  Comparison of ID8 MOSE and VEGF-modified ID8 cell lines in an immunocompetent animal model for human ovarian cancer. , 2006, Anticancer research.

[45]  Kunle Odunsi,et al.  Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. , 2006, Gynecologic oncology.

[46]  J. Cheng,et al.  Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[48]  W. Janssen,et al.  Cell-Surface Calreticulin Initiates Clearance of Viable or Apoptotic Cells through trans-Activation of LRP on the Phagocyte , 2005, Cell.

[49]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[50]  M. Malumbres,et al.  Revisiting the “Cdk-Centric” View of the Mammalian Cell Cycle , 2005, Cell cycle.

[51]  M. Goodell,et al.  A distinct "side population" of cells with high drug efflux capacity in human tumor cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[52]  A. A. Andrade,et al.  The vaccinia virus-stimulated mitogen-activated protein kinase (MAPK) pathway is required for virus multiplication. , 2004, The Biochemical journal.

[53]  Gordon Stamp,et al.  Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. , 2002, Cancer research.

[54]  S. Libutti,et al.  Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. , 2001, Cancer research.

[55]  Alfonso Bellacosa,et al.  AKT plays a central role in tumorigenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[56]  V. Fadok,et al.  C1q and Mannose Binding Lectin Engagement of Cell Surface Calreticulin and Cd91 Initiates Macropinocytosis and Uptake of Apoptotic Cells , 2001, The Journal of experimental medicine.

[57]  D. Kohn,et al.  Immune response to green fluorescent protein: implications for gene therapy , 1999, Gene Therapy.

[58]  A. Aruffo,et al.  Characterization of the Heparan Sulfate and Chondroitin Sulfate Assembly Sites in CD44* , 1999, The Journal of Biological Chemistry.

[59]  B. Williams,et al.  Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays , 1998 .

[60]  C. Chung,et al.  Cell Surface Proteoglycans Are Necessary for A27L Protein-Mediated Cell Fusion: Identification of the N-Terminal Region of A27L Protein as the Glycosaminoglycan-Binding Domain , 1998, Journal of Virology.

[61]  Robert B Sim,et al.  Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[62]  C. Chung,et al.  A27L Protein Mediates Vaccinia Virus Interaction with Cell Surface Heparan Sulfate , 1998, Journal of Virology.

[63]  A. S. Conner,et al.  Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo , 1996, The Journal of experimental medicine.

[64]  J. Thigpen,et al.  Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  J. Mehrishi.  Positively charged amino groups on the surface of normal and cancer cells. , 1970, European journal of cancer.

[66]  W. Halford,et al.  Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[67]  B. Teicher.  Antiangiogenic agents and targets: A perspective. , 2011, Biochemical pharmacology.

[68]  L. Zitvogel,et al.  Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.